PS5:105 Hdl inhibits t cell proliferation is sle. (21st March 2018)
- Record Type:
- Journal Article
- Title:
- PS5:105 Hdl inhibits t cell proliferation is sle. (21st March 2018)
- Main Title:
- PS5:105 Hdl inhibits t cell proliferation is sle
- Authors:
- Fernandes Das Neves, M
Favas, C
Batuca, J
Jury, EC
Alves, José Delgado - Abstract:
- Abstract : Purpose: Systemic lupus erythematosus (SLE) is associated with dyslipidemia and increased cardiovascular risk. The SLE pattern is characterised by high plasma levels of low-density lipoproteins (LDL) and triglycerides and low levels of high-density lipoproteins (HDL). HDL is a complex plasma lipoprotein that is recognised for its protective role in atherosclerotic disease. It consists of an outer layer of lipids and apolipoproteins, with apolipoproteinA-1 (apoA-1) constituting 70% of the protein content, a triglyceride and cholesterol ester-rich core, and several enzymes. In addition to its anti-atherogenic properties, mainly associated with reverse cholesterol transport from vessels, HDL has also anti-inflammatory properties that are not clearly understood. This work aims to show the effect of HDL on T lymphocyte proliferation. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 7 SLE patients, with at least 4 SLICC/ACR classification criteria and normal serum lipid profiles, and 3 healthy donors. PBMCs were cultured with and without HDL (at the concentrations of 50, 300 and 600 µg/mL) before CD3 and CD28 stimulation. After 4 days in culture, T cell proliferation was measured by flow cytometry through Ki-67 staining. Regulator T cells (Tregs) phenotyping (CD4 +CD25+CD27-FoxP3+) was performed. The expression of the cholesterol transporter ABCA1 in T lymphocytes was also measured by flow cytometry. Results: HDL decreased T cell proliferation in aAbstract : Purpose: Systemic lupus erythematosus (SLE) is associated with dyslipidemia and increased cardiovascular risk. The SLE pattern is characterised by high plasma levels of low-density lipoproteins (LDL) and triglycerides and low levels of high-density lipoproteins (HDL). HDL is a complex plasma lipoprotein that is recognised for its protective role in atherosclerotic disease. It consists of an outer layer of lipids and apolipoproteins, with apolipoproteinA-1 (apoA-1) constituting 70% of the protein content, a triglyceride and cholesterol ester-rich core, and several enzymes. In addition to its anti-atherogenic properties, mainly associated with reverse cholesterol transport from vessels, HDL has also anti-inflammatory properties that are not clearly understood. This work aims to show the effect of HDL on T lymphocyte proliferation. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 7 SLE patients, with at least 4 SLICC/ACR classification criteria and normal serum lipid profiles, and 3 healthy donors. PBMCs were cultured with and without HDL (at the concentrations of 50, 300 and 600 µg/mL) before CD3 and CD28 stimulation. After 4 days in culture, T cell proliferation was measured by flow cytometry through Ki-67 staining. Regulator T cells (Tregs) phenotyping (CD4 +CD25+CD27-FoxP3+) was performed. The expression of the cholesterol transporter ABCA1 in T lymphocytes was also measured by flow cytometry. Results: HDL decreased T cell proliferation in a dose-dependent manner, with the biggest effect obtained with the physiologic concentration of 600 µg/mL. The inhibition of T cell proliferation was more pronounced in SLE patients than in the healthy donors. SLE patients tend to have higher baseline T cell proliferation measured by ki-67 expression. There were no differences in the prevalence of Tregs among patients and healthy donors. The expression of ABCA1 on the surface of T lymphocytes was similar between groups. Conclusions: This study is the first demonstration of a regulatory effect of HDL on the adaptive immune system of SLE patients. Here we show that HDL can decrease T cell proliferation, which is not correlated with the expression of the ABCA1, the main cholesterol transporter to ApoA-1. We expect to further elucidate HDL effects on the immune system in future studies. … (more)
- Is Part Of:
- Lupus science & medicine. Volume 5(2018)Supplement 1
- Journal:
- Lupus science & medicine
- Issue:
- Volume 5(2018)Supplement 1
- Issue Display:
- Volume 5, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 5
- Issue:
- 1
- Issue Sort Value:
- 2018-0005-0001-0000
- Page Start:
- A88
- Page End:
- A88
- Publication Date:
- 2018-03-21
- Subjects:
- Lipoproteins -- Lymphocyte -- Lupus
Systemic lupus erythematosus -- Periodicals
616.772005 - Journal URLs:
- http://www.bmj.com/archive ↗
http://lupus.bmj.com/ ↗ - DOI:
- 10.1136/lupus-2018-abstract.150 ↗
- Languages:
- English
- ISSNs:
- 2398-8851
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19845.xml